Prophylaxis in Hemophilia

Detalhes bibliográficos
Autor(a) principal: Catelli, Dayenne
Data de Publicação: 2023
Outros Autores: Portich, Júlia Plentz, Tabares Calvache, Ebellins, Seganfredo Weber, Cristiane, Sander Hoffmann, Daniel, Rasia Bosi, Guilherme, Sekine, Leo, da Rocha Silla, Lucia Mariano
Tipo de documento: Artigo
Idioma: por
Título da fonte: Clinical and Biomedical Research
Texto Completo: https://seer.ufrgs.br/index.php/hcpa/article/view/126436
Resumo: Hemophilia is an inherited X-linked coagulopathy defined by a deficiency or abnormality in the clotting function of factor VIII (Hemophilia A) or factor IX (Hemophilia B). Prophylaxis – the regular administration of therapeutic products to maintain hemostasis and prevent bleeding – is the mainstream of treatment. Addressing the development and scientific evidence for administrating prophylaxis is the goal of this review. Prophylaxis is the therapeutic modality of choice for people with severe hemophilia, being considered, in principle, a lifelong treatment. It should have an early onset, ideally as a primary, or at least secondary. Even lifelong tertiary prophylaxis seems to offer benefit, although further studies are still lacking. Individualized strategies should lead to an optimization of the dilemma between better joint outcomes versus involved costs.
id UFRGS-20_b25755e0d4e087ce5f26ff6d0c6c59d0
oai_identifier_str oai:seer.ufrgs.br:article/126436
network_acronym_str UFRGS-20
network_name_str Clinical and Biomedical Research
repository_id_str
spelling Prophylaxis in HemophiliaHemophilia AHemophilia BProphylaxisHemophilia is an inherited X-linked coagulopathy defined by a deficiency or abnormality in the clotting function of factor VIII (Hemophilia A) or factor IX (Hemophilia B). Prophylaxis – the regular administration of therapeutic products to maintain hemostasis and prevent bleeding – is the mainstream of treatment. Addressing the development and scientific evidence for administrating prophylaxis is the goal of this review. Prophylaxis is the therapeutic modality of choice for people with severe hemophilia, being considered, in principle, a lifelong treatment. It should have an early onset, ideally as a primary, or at least secondary. Even lifelong tertiary prophylaxis seems to offer benefit, although further studies are still lacking. Individualized strategies should lead to an optimization of the dilemma between better joint outcomes versus involved costs.HCPA/FAMED/UFRGS2023-05-29info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionPeer-reviewed ArticleAvaliados por Paresapplication/pdfhttps://seer.ufrgs.br/index.php/hcpa/article/view/126436Clinical & Biomedical Research; Vol. 43 No. 1 (2023): Clinical and Biomedical ResearchClinical and Biomedical Research; v. 43 n. 1 (2023): Clinical and Biomedical Research2357-9730reponame:Clinical and Biomedical Researchinstname:Universidade Federal do Rio Grande do Sul (UFRGS)instacron:UFRGSporhttps://seer.ufrgs.br/index.php/hcpa/article/view/126436/88723Copyright (c) 2023 Dayenne Catelli, Júlia Plentz Portich, Ebellins Tabares Calvache, Cristiane Seganfredo Weber, Daniel Sander Hoffmann, Guilherme Rasia Bosi, Leo Sekine, Lucia Mariano da Rocha Sillahttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessCatelli, DayennePortich, Júlia PlentzTabares Calvache, Ebellins Seganfredo Weber, Cristiane Sander Hoffmann, Daniel Rasia Bosi, Guilherme Sekine, Leoda Rocha Silla, Lucia Mariano 2024-01-19T14:11:35Zoai:seer.ufrgs.br:article/126436Revistahttps://www.seer.ufrgs.br/index.php/hcpaPUBhttps://seer.ufrgs.br/index.php/hcpa/oai||cbr@hcpa.edu.br2357-97302357-9730opendoar:2024-01-19T14:11:35Clinical and Biomedical Research - Universidade Federal do Rio Grande do Sul (UFRGS)false
dc.title.none.fl_str_mv Prophylaxis in Hemophilia
title Prophylaxis in Hemophilia
spellingShingle Prophylaxis in Hemophilia
Catelli, Dayenne
Hemophilia A
Hemophilia B
Prophylaxis
title_short Prophylaxis in Hemophilia
title_full Prophylaxis in Hemophilia
title_fullStr Prophylaxis in Hemophilia
title_full_unstemmed Prophylaxis in Hemophilia
title_sort Prophylaxis in Hemophilia
author Catelli, Dayenne
author_facet Catelli, Dayenne
Portich, Júlia Plentz
Tabares Calvache, Ebellins
Seganfredo Weber, Cristiane
Sander Hoffmann, Daniel
Rasia Bosi, Guilherme
Sekine, Leo
da Rocha Silla, Lucia Mariano
author_role author
author2 Portich, Júlia Plentz
Tabares Calvache, Ebellins
Seganfredo Weber, Cristiane
Sander Hoffmann, Daniel
Rasia Bosi, Guilherme
Sekine, Leo
da Rocha Silla, Lucia Mariano
author2_role author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Catelli, Dayenne
Portich, Júlia Plentz
Tabares Calvache, Ebellins
Seganfredo Weber, Cristiane
Sander Hoffmann, Daniel
Rasia Bosi, Guilherme
Sekine, Leo
da Rocha Silla, Lucia Mariano
dc.subject.por.fl_str_mv Hemophilia A
Hemophilia B
Prophylaxis
topic Hemophilia A
Hemophilia B
Prophylaxis
description Hemophilia is an inherited X-linked coagulopathy defined by a deficiency or abnormality in the clotting function of factor VIII (Hemophilia A) or factor IX (Hemophilia B). Prophylaxis – the regular administration of therapeutic products to maintain hemostasis and prevent bleeding – is the mainstream of treatment. Addressing the development and scientific evidence for administrating prophylaxis is the goal of this review. Prophylaxis is the therapeutic modality of choice for people with severe hemophilia, being considered, in principle, a lifelong treatment. It should have an early onset, ideally as a primary, or at least secondary. Even lifelong tertiary prophylaxis seems to offer benefit, although further studies are still lacking. Individualized strategies should lead to an optimization of the dilemma between better joint outcomes versus involved costs.
publishDate 2023
dc.date.none.fl_str_mv 2023-05-29
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
Peer-reviewed Article
Avaliados por Pares
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://seer.ufrgs.br/index.php/hcpa/article/view/126436
url https://seer.ufrgs.br/index.php/hcpa/article/view/126436
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://seer.ufrgs.br/index.php/hcpa/article/view/126436/88723
dc.rights.driver.fl_str_mv https://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv HCPA/FAMED/UFRGS
publisher.none.fl_str_mv HCPA/FAMED/UFRGS
dc.source.none.fl_str_mv Clinical & Biomedical Research; Vol. 43 No. 1 (2023): Clinical and Biomedical Research
Clinical and Biomedical Research; v. 43 n. 1 (2023): Clinical and Biomedical Research
2357-9730
reponame:Clinical and Biomedical Research
instname:Universidade Federal do Rio Grande do Sul (UFRGS)
instacron:UFRGS
instname_str Universidade Federal do Rio Grande do Sul (UFRGS)
instacron_str UFRGS
institution UFRGS
reponame_str Clinical and Biomedical Research
collection Clinical and Biomedical Research
repository.name.fl_str_mv Clinical and Biomedical Research - Universidade Federal do Rio Grande do Sul (UFRGS)
repository.mail.fl_str_mv ||cbr@hcpa.edu.br
_version_ 1799767057569415168

Registros relacionados